Current Report Filing (8-k)
April 22 2019 - 5:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 17, 2019
ASSEMBLY BIOSCIENCES, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-35005
|
|
20-8729264
|
(State or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
11711 N. Meridian St., Suite 310
Carmel, Indiana 46032
|
(Address of principal executive offices, including zip code)
|
(317) 210-9311
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company
o
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
o
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Compensatory Arrangements of Certain Officers.
(b)
On April 17, 2019, Assembly Biosciences, Inc. (the “Company”)
and Uri A. Lopatin, M.D., its Chief Medical Officer and a named executive officer of the Company, announced that he is stepping
down as Chief Medical Officer effective as of the close of business on May 6, 2019, and will transition to a clinical and scientific
advisor role. Dr. Lopatin will transition his clinical development duties to the Company’s newly hired Senior Vice President,
Clinical Development, Steven J. Knox. The Company has a search underway for a chief medical officer candidate to replace Dr. Lopatin.
Dr. Lopatin will remain with the Company as a clinical and scientific advisor. The terms of this consulting
arrangement have not been finalized.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 22, 2019
|
Assembly Biosciences, Inc.
|
|
|
|
|
|
|
|
By:
|
/s/ Derek A. Small
|
|
|
Derek A. Small
|
|
|
President and Chief Executive Officer
|
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Apr 2023 to Apr 2024